Abstract
The design and synthesis of novel 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamide CB2 selective ligands for the potential treatment of pain is described. Compound (R,R)-25 has good balance between CB2 agonist potency and selectivity over CB1, and possesses overall favorable pharmaceutical properties. It also demonstrated robust in vivo efficacy mediated via CB2 activation in the rodent models of inflammatory and osteoarthritis pain after oral administration.
Keywords:
CB2 agonist; Cannabinoid 2 receptor; Pain.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Analgesics, Non-Narcotic / administration & dosage
-
Analgesics, Non-Narcotic / chemistry
-
Analgesics, Non-Narcotic / pharmacology*
-
Animals
-
Arthritis, Experimental / drug therapy
-
Arthritis, Experimental / metabolism
-
Heterocyclic Compounds, 3-Ring / administration & dosage
-
Heterocyclic Compounds, 3-Ring / chemistry
-
Heterocyclic Compounds, 3-Ring / pharmacology*
-
Humans
-
Inflammation / drug therapy*
-
Inflammation / metabolism
-
Male
-
Microsomes, Liver / drug effects*
-
Microsomes, Liver / metabolism
-
Models, Molecular
-
Molecular Structure
-
Osteoarthritis / drug therapy*
-
Osteoarthritis / metabolism
-
Pain / drug therapy*
-
Pain / metabolism
-
Pyrazoles / administration & dosage
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology*
-
Radioligand Assay
-
Rats
-
Rats, Sprague-Dawley
-
Receptor, Cannabinoid, CB1 / agonists
-
Receptor, Cannabinoid, CB2 / agonists*
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
Analgesics, Non-Narcotic
-
Heterocyclic Compounds, 3-Ring
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2